- Price is above Fair Value, showing premium demand versus the model.
OBCK
GER
Week ended 24 Jul 2026
Weekly Investor Report
Ottobock SE & Co. KGaA I · Healthcare · Medical Instruments & Supplies
Latest close
55.40 EUR
-3.7%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is - below the Trend Line and sits at 55.9% of its 52-week range. The latest completed week returned -3.7%, after a 6.5% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal.
Setup score
39
out of 100
Latest Close
55.40 EUR
24 Jul 2026
1W Return
-3.7%
latest completed week
4W Return
6.5%
short-term follow-through
12W Return
-3.2%
quarterly tape
Trend Breadth
0.0%
0 of 26 weeks active
Volume Ratio
0.6x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-3.7%
Latest completed week; four-week move 6.5%.
Indicator stack
0/50
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
52/100
10 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is - below the Trend Line and sits at 55.9% of its 52-week range. The latest completed week returned -3.7%, after a 6.5% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1212-week average 0.16
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.12Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 6.5% over four weeks, -3.2% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 76%
Model confidence 73%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength29/100Blend of value, momentum, and quality. Underlying universe rank 72; rank 1 is best.
Value21/100Relative valuation strength. Underlying universe rank 80; rank 1 is best.
Quality83/100Profitability and accounting quality. Underlying universe rank 18; rank 1 is best.
Momentum43/100Medium-term price momentum. Underlying universe rank 58; rank 1 is best.
Growth42/100Revenue and earnings growth. Underlying universe rank 59; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework46/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 39.3x Price divided by trailing earnings.
- Price / sales
- 2.1x Market value relative to trailing revenue.
- EV / EBITDA
- 11.8x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 5.0% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 52.8% Gross profit retained from each unit of revenue.
- Operating margin
- 13.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 13.4% Free cash flow generated from revenue.
- Return on invested capital
- 12.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 1.8% Cash dividends relative to market value.
- Buyback yield
- -2.8% Net share repurchases relative to market value.
- Shareholder yield
- -1.1% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 10 relevant articles.
2 positive · 7 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-13.2%Distance below the 52-week high.
13-week volatility6.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher13 of 2512 weeks finished lower.
Best week+14.8%Week of 17 Jul.
Worst week-12.9%Week of 20 Mar.
Latest week-3.7%Week of 24 Jul.
Shape of recent returns
Strong gains4
Modest gains9
Flat weeks0
Modest losses5
Sharp losses7
Recent vol6.1%13-week weekly-return volatility.
Base vol6.3%52-week weekly-return volatility.
Up/down split13/12Count of positive and negative weeks in the 52-week window.
Average skew4.5% / -5.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank17 / 78
Group average1.5%
Trend breadth38.5%
Trend38.5%active weekly trend signals
MD64.1%positive activity pressure
RS43.6%positive relative leadership
Four-week leaders
IndustryDE Medical Instruments & Supplies
4-week rank2 / 12
Group average-0.6%
Trend breadth16.7%
Trend16.7%active weekly trend signals
MD66.7%positive activity pressure
RS8.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape34/100
Trend, activity pressure, participation, and risk combine to a 34/100 tape read.
Indicator analysis11/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.12; No reversal markers Factors43/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 95; Small Cap Core rank 90 SVQF46/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 203.5 of 373 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment52/100Weighted news tone is neutral across 10 relevant articles.
Ottobock SE & Co. KGaA Revenue Breakdown – DUS:OBCK Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 55.40 EUR | -3.7% | - | 54.90 EUR | 0.00 | - | 78.2K | Off |
| 17 Jul 2026 | 57.50 EUR | 14.8% | - | 54.88 EUR | 0.00 | - | 183.8K | Off |
| 10 Jul 2026 | 50.10 EUR | -7.4% | - | 54.77 EUR | 0.00 | - | 136.4K | Off |
| 3 Jul 2026 | 54.10 EUR | 4.0% | - | 54.98 EUR | 0.00 | - | 74.0K | Off |
| 26 Jun 2026 | 52.00 EUR | 3.4% | - | 55.02 EUR | 0.00 | - | 103.1K | Off |
| 19 Jun 2026 | 50.30 EUR | -1.4% | - | 55.16 EUR | 0.00 | - | 407.8K | Off |
| 12 Jun 2026 | 51.00 EUR | -6.8% | - | 55.40 EUR | 0.00 | - | 21.2K | Off |
| 5 Jun 2026 | 54.70 EUR | 3.6% | - | 55.64 EUR | 0.00 | - | 21.4K | Off |
| 29 May 2026 | 52.80 EUR | -5.9% | - | 55.69 EUR | 0.00 | - | 90.1K | Off |
| 22 May 2026 | 56.10 EUR | -7.8% | - | 55.86 EUR | 0.00 | - | 362.2K | Off |
| 15 May 2026 | 60.88 EUR | 3.3% | - | 55.84 EUR | 0.00 | - | 133.3K | Off |
| 8 May 2026 | 58.91 EUR | 2.9% | - | 55.51 EUR | 0.00 | - | 118.5K | Off |
| 1 May 2026 | 57.24 EUR | -0.5% | - | 55.26 EUR | 0.00 | - | 45.7K | Off |
| 24 Apr 2026 | 57.54 EUR | -0.8% | - | 55.11 EUR | 0.00 | - | 83.2K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.